Core Viewpoint - BioPorto A/S has successfully completed a private placement of 40,438,426 new shares, raising approximately DKK 43 million, which will enhance the company's financial flexibility to pursue strategic priorities and strengthen its commercial platform [1][2]. Group 1: Private Placement Details - The private placement involved 40,438,426 new shares and is expected to generate gross proceeds of around DKK 43 million [1][2]. - The subscription price for the new shares is scheduled to be paid by 24 November 2025, with the share capital increase registration to follow shortly thereafter [2]. - BioPorto anticipates that the new shares will be listed on Nasdaq Copenhagen A/S by no later than 26 November 2025 [2]. Group 2: Strategic Implications - The funds raised will support the completion of data collection, submission of a pre-submission to the FDA, and initiation of a Validation Study in the U.S. clinical trial [2]. - The Board of BioPorto has considered various future financing options, including potential divestments of non-core assets and credit facilities, to ensure a balanced funding structure [2]. - The company aims to position itself for positive cash flow by the second half of 2027 [2]. Group 3: Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable kidney biomarkers to improve patient management and outcomes [4][5]. - The flagship products are based on the NGAL biomarker, which aids in the risk assessment and management of Acute Kidney Injury (AKI) [5]. - BioPorto's tests are marketed under various registrations, including CE mark and FDA clearance for ProNephro AKI™ in the U.S. [5].

Core Viewpoint - SEACOR Marine Holdings Inc. has published its 2024-2025 Sustainability Report, emphasizing its commitment to environmental responsibility, employee welfare, and community engagement [1][2]. Environmental Commitment - The report highlights SEACOR Marine's efforts to enhance environmental sustainability and operational efficiency, including the expansion of its hybrid platform supply vessel fleet and investments in green technologies [6]. - The company is focused on waste reduction initiatives both on vessels and in offices, aiming to integrate sustainable practices throughout its operations [6]. Employee Welfare - SEACOR Marine is dedicated to fostering a safe and inclusive work environment, with initiatives aimed at promoting the mental and emotional well-being of seafarers, including high-speed satellite internet across its fleet [6]. - The company continues to pursue its GOAL ZERO safety vision, which has led to measurable improvements in safety performance [6]. Community Engagement - SEACOR Marine supports local organizations and social welfare initiatives through financial contributions and volunteer efforts, ensuring meaningful impact in the communities where it operates [6]. - The company prioritizes partnerships with local suppliers and collaborates with community stakeholders to drive shared progress [6]. Industry Standards - The sustainability report aligns with the industry-specific standards set by the Sustainability Accounting Standards Board (SASB) and identifies relevant United Nations Sustainable Development Goals (UN SDGs) [3].

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- All per share figures disclosed below are stated on a diluted basis. For the periods ended September 30,Three months Nine months($ in thousands, except per share amounts) 2025 2024(2) 2025 2024(2) ...

SAN FRANCISCO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (NASDAQ: BRLT), an innovative, global leader in ethically sourced fine jewelry, today announced that the Company will participate in upcoming investor events. On November 19, 2025, the Company will participate in the 14th Annual Roth Technology Conference being held at the Hard Rock Hotel New York in New York City. Management will hold investor meetings throughout the day. On November 20, 2025, ...

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Figure Technology Solutions, Inc. (“FTS”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC"), relating to the proposed public offering of its Series A Blockchain Common Stock, par value $0.0001 per share (the “Tokenized Stock”). The Tokenized Stock will not be listed on any legacy exchange, but will trade on Figure’s alternative trading system and will be conv ...

Core Points - RAMM Pharma Corp. has received approval from its minority shareholders for a proposed investment transaction with The Global South S.A.S. [1] - The transaction involves a US$5 million investment for a 10% equity interest in The Global South, with a post-investment valuation of US$50 million [2] - RAMM will have a call option to acquire an additional 15% equity interest, potentially increasing its total ownership to 25% at a future valuation of US$400 million [2] - The completion of the transaction is contingent upon negotiation of definitive documentation and receipt of regulatory approvals [3] Company Overview - RAMM Pharma is engaged in cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and hemp products, with a diversified international production and sales platform [4] - The company's operations in Europe include extraction and processing facilities in Italy and Poland, with subsidiaries such as Canapar Corp. and HemPoland [5][6]

Highlights Net revenue of $1.7 billion, an increase of 11.8% compared to Q3 2024Adjusted EBITDA1 increase of 17.8% to $323.4 million and adjusted EBITDA margin1 of 19.0%, a 100 basis point increase over Q3 2024Diluted EPS of $1.32 and adjusted EPS1 of $1.53, up 46.7% and 17.7%, respectively, compared to Q3 2024Contract backlog increased to $8.4 billion, up 14.9% year-over-yearIncreases full year adjusted EBITDA margin guidance, reflecting the strong performance year-to-date and expectations for Q4 2025. EDM ...

Los Angeles, CA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- OFA Group (NASDAQ: OFAL) (“OFA” or the “Company”), an international architecture, technology, and digital-asset infrastructure company, today announced that its Extraordinary General Meeting of Shareholders (“EGM”), originally scheduled for November 5, 2025, has been rescheduled to November 24, 2025 at 5:00 p.m. Eastern Time. The meeting will be held exclusively in a virtual format via electronic communication facilities. Instructions for accessing the meet ...

Adjusted EBITDA from continuing operations of $1.2 million for the nine months ended September 30, 2025, compared to a loss of $0.1 million in the year ago period Completed sale of Direct Sales Media Business and related creative assets in Q3, resulting in a gain on sale of subsidiaries and assets of $5.5 million Gross margin of 86.9% in Q3 2025, up 1,810 bps from Q3 2024 TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a digital ...

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose LevelsPatients are Now Being Treated at 160 mg Dose of Tuspetinib SAN DIEGO and TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with ne ...